ACAlexandra Cambier

Alexandra Cambier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Cambier has a total of 160 co-authors. Here are the top co-authors by number of shared publications:

  • Anne-Laure Lapeyraque

    Division of Nephrology, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Quebec, Canada

    5 shared publications
  • Lison Lachize Neanne

    Center of research Azrieli, CHU Sainte-Justine, Montreal, Canada

    4 shared publications
  • Natacha Patey

    Centre de Recherche axe Immunologie, Université de Montréal, CHU Sainte Justine Montréal, Canada

    4 shared publications
  • Claire Dossier

    Department of Pediatric Nephrology, Robert-Debré Hospital, APHP, Paris, France

    3 shared publications
  • Olivia Boyer

    APHP. Centre, Institut Imagine, Néphrologie Pédiatrique, Centre de Référence MARHEA, Hôpital Necker-Enfants Malades, Université Paris Cité, Paris, France

    3 shared publications
  • Renato C. Monteiro

    Center for Research on Inflammation, Paris Cité University, INSERM and CNRS, Paris, France

    3 shared publications

Latest Publications

  • Une étude translationnelle de la néphropathie à IgA de l’enfant : des variants génétiques à la physiopathologie des biomarqueurs et leurs liens de causalité avec les lésions histologiques

    by Alexandra Cambier

    La N-IgA est une maladie auto-immune impliquant 3 biomarqueurs, les IgA1 hypogalactosylées (Gd)-lgA1,des auto-anticorps IgG anti-Gd-IgA1 et le récepteur soluble (s) CD89 IgA Fc lié à l'IgA (sCD89-IgA). Le sCD8 en circulation sous forme libre ou complexé aux IgA serait un acteur clé de la prolifération mésangiale suite à une interaction avec le récepteur CD71. Les complexes sCD89-IgA et le sCD89 libre étaient fortement liés à la protéinurie et aux lésions histologiques de prolifération in vivo et in vitro. Ces découvertes révèlent un nouveau rôle du sCD89 comme biomarqueur et comme potentielle cible thérapeutique dans la N-IgA de l'enfant. Ces complexes immuns pourraient représenter un outil utile pour éviter les biopsies rénales répétées et suivre la réponse aux traitements. Des travaux antérieurs ont suggéré que des néphropathies dites familiales pourraient être en lien avec la région 2q36 du chromosome, qui est également la région codante pour COL4A3/A4. La N-IgA de l'enfant présentant des variants hétérozygotes pathologiques COL4A3 doit être considérée comme un facteur de prédisposition quant au développement d'une N-IgA sévère. Les variants pathogènes COL4A3 découverts au stade précoce pourraient représenter un outil utile pour stratifier la gravité de la N-IgA de l'enfant au-delà de la classification d'Oxford.

  • Hydroxychloroquine use in pediatric IgA nephropathy

    by Karma Abukasm, Lison Lachize Neanne, Andrea Lafitte, Zoe Reverand, Véronique Phan, Olivia Boyer, Geneviève Benoit, Kevin Côté, Marion Rabant, Anne-Laure Lapeyraque, et al.

    Background Hydroxychloroquine (HCQ) has been identified as an interesting treatment option in adult IgA nephropathy. HCQ targets the active toll-like receptors in IgA nephropathy. The purpose of this study was to explore the effects and potential benefits of HCQ for childhood-onset IgA nephropathy (cIgAN). Methods We conducted a retrospective multicenter cohort study including 16 children with biopsy-proven cIgAN treated with HCQ in tertiary pediatric nephrology centers in Canada and France. HCQ was prescribed as an adjunctive therapy for persistent proteinuria despite standard-of-care treatment and/or with a steroid-sparing intent. Clinical and histological data were collected at baseline, and urine protein-to-creatinine ratios (UPCR) and estimated glomerular filtration rates (eGFR) were documented at HCQ initiation, 3, 6, 9, and 12 months of follow-up. Iterative biopsies before and after the introduction of HCQ (n = 8) were compared. Steroid exposure was assessed in both groups, and safety monitoring data for HCQ therapy were documented. Results Median age was 12.74 [11.33–14.07] years, with 37.5% male participants. Most (15/16, 93.8%) participants received steroid therapy, and all (16/16, 100%) were treated with renin–angiotensin–aldosterone system blockers. HCQ was initiated within a median time of 519 [249–1016.5] days from initial diagnosis. UPCR at 3, 6, 9, and 12 months after HCQ initiation significantly decreased, both in absolute and relative metrics. A decrease of 50% was noted at 12 months of follow-up. eGFR remained stable over the follow-up period. Follow-up biopsies in the HCQ-treated group showed stability or improvement of the Oxford score. No complications of HCQ were documented. Conclusions In this first pediatric cohort reporting on real-life experience with HCQ, HCQ use was associated with a sustained reduction in proteinuria and stable kidney function in children with difficult-to-control cIgAN, with an excellent safety profile. Although causality cannot be inferred due to the observational design and concomitant therapies, these findings support further prospective evaluation of HCQ as a safe adjunctive treatment in selected cases of cIgAN. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information.

  • IgA nephropathy new therapies: from data in adults to application in children

    by Alexandra Cambier, Lison Lachize Neanne, Srishti Sahu, Laure Arbez, Nicolas Maillard

    IgA nephropathy (IgAN) is the most common primary glomerulonephritis, typically presenting early in life, often in young adults but also frequently in chil


  • Open Access

    Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized mice

    by Alexandra Cambier, Jennifer Da Silva, Julie Bex, Fanny Canesi, Lison Lachize Neanne, Aurélie Sannier, Hélène Mathieu, Erwan Boedec, Amandine Badie, Renato C. Monteiro

    Background and hypothesis: IgA nephropathy (IgAN) is the most common glomerulonephritis and major cause of renal failure worldwide. Its pathogenesis involves galactose deficient IgA1-immune complexes containing soluble IgA Fc receptor (sCD89). Both IgA1 and sCD89 bind independently to the transferrin receptor (TfR1, CD71), a mesangial IgA1 receptor. Here, we hypothesize that sCD89 plays a pathogenic role in IgAN by driving a tri-partite IgA1-sCD89-CD71 complex inducing activation in situ of the mTOR (mammalian target of rapamycin) signaling pathway in mesangial cells and contributing to disease progression. mTOR inhibition may disrupt this pathogenic axis, reducing IgA1 and sCD89 deposits, modulating CD71 expression, and alleviating disease manifestations. Here, we investigated the role of sCD89 and a mTOR inhibitor using humanized mouse models of IgAN expressing CD89 and/or IgA1. Methods: Single cell and RNAseq data were obtained from public IgAN dataset and immunostaining was performed on childhood IgAN (cIgAN) biopsies. Human mesangial cells (HMCs) stimulation by recombinant sCD89 (rsCD89) was followed by western blot analysis. Pre-clinical assays with mTOR inhibitor (Everolimus) by oral gavage were performed using young α1KI mice injected with rsCD89 for 25 days (preventive protocol) and adult α1KICD89Tg mice (treated protocol) for 75 days. Proteinuria, renal function, and circulating immune complexes (CICs) were analyzed and kidneys were harvested for histology. Results: RNAseq revealed increased TfR1 and mTOR expression in mesangial cells from IgAN patients. TfR1 upregulation was confirmed in cIgAN biopsies. sCD89 stimulation induced HMC TfR1 expression and phosphorylation of mTOR, Akt and S6K1. Everolimus treatment prevented or reverted mesangial IgA1 and C3 deposits and also decreased mesangial TfR1 and cell proliferation. Everolimus impaired levels of sCD89- and IgA-CIC, proteinuria, as well as renal function. Conclusion: These findings highlight the critical role of the sCD89-TfR1-mTOR axis in IgAN pathogenesis and support the use of mTOR inhibitors as a novel therapeutic approach. This approach could significantly improve outcomes by slowing disease progression and minimizing the systemic toxic effects of current immunosuppressive therapies. This is particularly crucial for pediatric patients, where the only approved treatment – steroids – has severe side effects, including detrimental impacts on bone health and growth.


  • Open Access

    Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized mice

    by Alexandra Cambier, Jennifer Da Silva, Julie Bex, Fanny Canesi, Lison Lachize, Aurélie Sannier, Natacha Patey, Erwan Boedec, Amandine Badie, Renato C. Monteiro

    Background and hypothesis: IgA nephropathy (IgAN) is the most common glomerulonephritis and major cause of renal failure worldwide. Pathogenesis involves galactose deficient IgA1-immune complexes containing soluble IgA Fc receptor (sCD89). Both IgA1 and sCD89 bind independently to transferrin receptor (TfR1, CD71), a mesangial IgA1 receptor. Here, we hypothesize that sCD89 plays a pathogenic role in IgAN by driving a tri-partite IgA1-sCD89-CD71 complex inducing activation in situ of the mTOR (mammalian target of rapamycin) signaling pathway in mesangial cells and contributing to disease progression. mTOR inhibition may disrupt this pathogenic axis, reducing IgA1 and sCD89 deposits, modulating CD71 expression, and alleviating disease manifestations. Here, we investigated the role of sCD89 and a mTOR inhibitor using humanized mouse models of IgAN expressing CD89 and/or IgA1. Methods: Single cell and RNAseq were obtained from IgAN public dataset and immunostaining from childhood IgAN (cIgAN) biopsies. Human mesangial cell (HMC) stimulation by recombinant sCD89 (rsCD89) was followed by western blot analysis. Pre-clinical assays with mTOR inhibitor (Everolimus) by oral gavage were performed using young α1 KI mice injected with rsCD89 for 25 days (preventive protocol) and adult α1 KI CD89 Tg mice (treated protocol) for 75 days. Proteinuria, renal function, and circulating immune-complexes (CIC) were analysed and kidneys harvested for histology. Results: RNAseq revealed increased TfR1 and mTOR mesangial cell expression in IgAN patients. TfR1 upregulation was confirmed in cIgAN biopsies. sCD89 stimulation induced HMC TfR1 expression and phosphorylation of mTOR, Akt and p70S6K1. Everolimus treatment prevented or reverted mesangial IgA1 and C3 deposits but also decreased mesangial TfR1 and cell proliferation. Everolimus impaired levels of sCD89- and IgA-CIC, proteinuria, as well as renal function. Conclusion: These findings highlight the critical role of the sCD89-TfR1-mTOR axis in IgAN pathogenesis and support the use of mTOR inhibitors as a novel therapeutic approach. This approach could significantly improve outcomes by slowing disease progression and minimizing the systemic toxic effects of current immunosuppressive therapies. This is particularly crucial for pediatric patients, where the only approved treatment – steroids – has severe side effects, including detrimental impacts on bone health and growth.

  • Open Access

    Bridging pediatric and adult IgAN: challenges in applying proteinuria-driven recommendations in the new IPNA guidelines

    by Alexandra Cambier, Claire Dossier, Anne-Laure Lapeyraque, Véronique Phan, Camille Laroche, Karma Abukasm, Genevieve Benoit, Jean-Philippe Roy, Julien Hogan, Olivia Boyer, et al.


  • Capacity for the management of kidney failure in the International Society of Nephrology North America and the Caribbean region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)

    by Racquel Lowe-Jones, Isabelle Ethier, Lori-Ann Fisher, Michelle M.Y. Wong, Stephanie Thompson, Georges Nakhoul, Shaifali Sandal, Rahul Chanchlani, Sara N. Davison, Anukul Ghimire, et al.


  • Open Access

    Unraveling the Role of Complement in Focal Segmental Glomerulosclerosis Pathogenesis: Insights and Challenges

    by Alexandra Cambier, Natacha Patey, Virginie Royal, François Gougeon, Dominique S. Genest, Soumeya Brachemi, Guillaume Bollée, Clémence Merlen, Arnaud Bonnefoy, Anne-Laure Lapeyraque, et al.